Bangkok – The Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, extends its heartfelt congratulations to Professor Kiat Ruxrungtham, M.D., and the ChulaVac006 Study Team for their historic success. The results of their clinical study on 'Comvigen,' a Thai-developed COVID-19 vaccine, have been published in the prestigious medical journal, The Lancet Regional Health - Southeast Asia. Chula CRC is proud to have been a part of driving and supporting this incredible achievement by the research team.

A Success Born from the Dedication of Thai Researchers

This publication is a testament to the capability, dedication, and vision of the Thai research team, who conducted a Phase 2 clinical trial to compare the efficacy and safety of the Comvigen vaccine against the Comirnaty Bivalent vaccine.

The team's proud accomplishments have demonstrated that:

• The Comvigen vaccine, developed and manufactured in Thailand, can effectively stimulate an immune response against both the original and Omicron BA.4/BA.5 variants of SARS-CoV-2, with results being non-inferior to the internationally recognized vaccine.

• The research team rigorously evaluated and confirmed the vaccine's safety profile, with the results meeting acceptable and satisfactory standards.

Chula CRC: Proud to Be Part of the Success

A monumental study such as this requires clinical trials conducted at the highest standards to produce credible data that is internationally accepted. Chula CRC is therefore deeply honored to have been entrusted by the researchers to serve as one of the four main clinical trial sites for this historic study.

We provided our full support to the researchers' work through efficient research management, expert medical personnel, and processes that adhere to international standards. This ensured the safety of our volunteers and the accuracy of the research data, which were critical factors in the study's success and its publication in a world-class journal.

Chula CRC once again applauds and celebrates the success of all the researchers. We stand ready to continue our role as a key supporter in advancing Thailand's medical research on the global stage.

Read the full study at: The Lancet Regional Health - Southeast Asia